Tomasz Czerw
A5006796325- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Eosinophilic Disorders and Syndromes
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Neutropenia and Cancer Infections
- Polyomavirus and related diseases
- Hemoglobinopathies and Related Disorders
- Viral-associated cancers and disorders
- Systemic Sclerosis and Related Diseases
- Mast cells and histamine
- Childhood Cancer Survivors' Quality of Life
- Mesenchymal stem cell research
- CNS Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Cancer Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Oral health in cancer treatment
- Lung Cancer Treatments and Mutations
The Maria Sklodowska-Curie National Research Institute of Oncology
2016-2025
Medical University of Warsaw
2023
Centrum Onkologii
2012-2019
John Wiley & Sons (United States)
2016
Collegium Medicum in Bydgoszcz
2015
Medical University of Silesia
2004-2010
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed outcome of 2224 patients with myelofibrosis (MF) who underwent allogeneic stem cell transplantation (allo-SCT) between 2000 2014; 781 (35%) myeloablative conditioning (MAC) 1443 (65%) reduced-intensity (RIC). Median patient age was 52.9 years (range, 18 to 74 years) 57.5 21 76 in MAC RIC cohorts, respectively. Donor type similar: matched sibling donors (MAC, 317 [41%]; RIC, 552 [38%]) unrelated 464...
Abstract Splenomegaly is the clinical hallmark of myelofibrosis. at time allogeneic hematopoietic cell transplantation (HCT) associated with graft failure and poor function. Strategies to reduce spleen size before HCT especially after Janus kinase (JAK) inhibition represent unmet needs in field. Here, we leveraged a global collaboration investigate safety efficacy splenic irradiation as part platform for patients We included 59 patients, receiving within median 2 weeks (range, 0.9–12 weeks)...
// Tomasz Czerw 1 , Myriam Labopin 2,3,4 Christoph Schmid 5 Jan J. Cornelissen 6 Patrice Chevallier 7 Didier Blaise 8 Jürgen Kuball 9 Stephane Vigouroux 10 Frédéric Garban 11 Bruno Lioure 12 Nathalie Fegueux 13 Laurence Clement 14 Anna Sandstedt 15 Johan Maertens 16 Gaëlle Guillerm 17 Dominique Bordessoule 18 Mohamad Mohty 2,3,4,* and Arnon Nagler 19,2,* Department of Bone Marrow Transplantation Oncohematology, Maria Sklodowska-Curie Memorial Cancer Centre Institute Oncology, Gliwice Branch,...
Abstract The role of spleen size and splenectomy for the prediction post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort 1195 patients transplanted between 2000‐2017 after either fludarabine‐busulfan or fludarabine‐melphalan regimens. Overall, was performed 202 (16.9%) its use decreased over time (28.3% 2000‐2009 vs 14.1% 2010‐2017 period). By multivariate analysis, associated with less NRM (HR...
Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study BP-MPN undergoing allo-HCT. first allo-HCT between 2005 2019 were included. A total 663 With median follow-up 62 months, estimated 3-year overall survival (OS) was 36% (95%...
Autologous stem cell transplantation (ASCT) for adult acute myelogenous leukemia (AML) is a valid therapeutic option patients with good-risk and intermediate-risk disease. The authors used the registry of European Society Blood Marrow Transplantation to compare combined busulfan melphalan (BUMEL) cyclophosphamide (BUCY) before transplantation.From 2005 2013, 853 available cytogenetics underwent ASCT in first remission, including 257 after receiving BUMEL 596 BUCY. proportion AML was lower...
Leukemia recurrence is a major cause of treatment failure after autologous stem cell transplantation for acute myeloid leukemia (AML). It usually occurs within the first 2 years transplantation. The goal current retrospective study was to assess follow-up and characterize risk factors outcome among patients who survived free disease this period.The analysis included 3567 adults (median age, 45 years) with AML underwent autografting during (86% patients) or second (14% complete remission...
Abstract Allogeneic hematopoietic cell transplantation (allo‐HCT) is increasingly used in older myelofibrosis (MF) patients, but its risk/benefit ratio compared to non‐transplant approaches has not been evaluated this population. We analyzed the outcomes of allo‐HCT 556 MF patients aged ≥65 years from EBMT registry, and determined excess mortality over matched general population managed with (n = 556) or conventional drug treatment 176). The cohort included intermediate‐2 high risk DIPSS...
To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) myelofibrosis (MF), we examined the data of 623 allo-HCT between 2000 and 2016 in United States (the Center International Blood Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable was used to identify factors mortality. weighted score using these assigned who received Europe European Bone [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95%...
'Non-classical' Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative (MDS/MPNs) represent a heterogeneous group of malignancies characterized by wide range clinical manifestations. Unlike classical MPNs, there is no standardized management approach for these conditions, particularly concerning the indications allogeneic hematopoietic cell transplantation (HCT). To address this gap, EBMT Practice Harmonization Guidelines (PH&G) Committee Chronic Malignancies Working...
Abstract Objectives: Killer immunoglobulin‐like receptors (KIRs) regulate function of natural killer (NK) cells and a subset T cells. In this study, we prospectively evaluated the impact donor recipient activating KIR genes on outcome allogeneic hematopoietic stem cell transplantation (alloHSCT) for patients with hematological malignancies. Methods: One‐hundred consecutive recipients myeloablative their donors were tested genotype as well immune reconstitution, including expression NK...
The procedure of autologous hematopoietic stem/progenitor cell transplantation requires cryopreservation. Addition DMSO is necessary to secure the viability such cells, but this solvent potentially toxic stem cells' recipient. 10% solution used by majority transplant centres. aim our study was test if concentration might be reduced without negative impact on recovery and clonogenicity.Samples were prospectively collected from 20 patients. Small volumes leukapheresis products frozen with...
Mobilized peripheral blood stem cells are currently the predominant source of grafts for allogeneic transplantation (allogeneic cell [allo-PBSCT]), although, in comparison with bone marrow, their use is associated an increased risk chronic graft-versus-host disease (cGVHD). Attempts to reduce incidence cGVHD include addition anti-thymocyte globulin (ATG) pretransplant conditioning regimen.The goal this retrospective study was analyze effect ATG on allo-PBSCT outcomes adults...